Global Health IPO Review & Recommendations

Apply for Listing Gain at Cut-off Price

Barring poor GMP (12), high OFS (1700 cr), and low post-IPO promoter holding (33), I see some potential in this hospital stock. Hospitals have been usually well-received by the markets, plus the decent subscription levels tell me this may be a good bet even for longterm. Taking the gamble. 5 red flags out of 13.

Neutral

In waves of MAIN BOARD & SMES ipo, this will have a tough competition.
Listing gain may be surprising.

Apply for Listing Gain at Upper Price Band

This is THE Brand with reasonable valuation, Must subscribe.

Avoid

Uncertaintey

Apply for Long Term at Cut-off Price

Fundamentally strong Company.
Brand Value
World ke Top 200 Hospitals Mein ek hai "Medanta"
KhelaHobe
खेला होबे
খেলা হবে

1

Apply for Long Term at Cut-off Price

Great brand value, high-quality business, solid management. Growth path in place, and new hospitals ramping up fast. Valued at 18.5x FY22 EBITDA, whereas peers trade at average of 25x, so attractive pricing.

Avoid

Instead of applying in such poor quality IPO like Fusion and Global health its better to buy good quality scrips from secondary market which are trading at cheap valuations. Few of my suggestions to buy would be : Sanofi India, Johnson Control, Tamilnad Merchantile Bank, GE T&D India, Bector Foods, Railtel etc,

Apply for Long Term at Upper Price Band

Available at reasonable valuations compared to Apollo, Fortis.

Neutral

IPO pricing is at its fair value.
Good Brand.
Good for Long term.

1

Neutral

May Apply

Avoid

HUGE OFS ISSUE. NOT FAIRLY PRICED AND POST ISSUE HOLDING WILL JUST 33%.

Apply for Listing Gain at Upper Price Band

Many people are comparing it with max hospital and inferring Medanta costly but how. Max with 600 crores profit has market cap of 41000 crores while Medanta with 200 crores profit seems to have market cap of 8000 crores. Can anyone shed light on this.

Apply for Short Term at Cut-off Price

Attractively priced. Though share is good for long term also but in short term prices may run ahead of fundamentals